GlaxoSmithKline PLC’s (GSK) “Hold” Rating Reaffirmed at Shore Capital

GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “hold” rating reiterated by investment analysts at Shore Capital in a research note issued to investors on Wednesday.

GlaxoSmithKline PLC (NYSE:GSK) traded up 2.17% during midday trading on Wednesday, reaching $45.12. 6,005,111 shares of the company were exchanged. The firm has a market capitalization of $109.60 billion and a PE ratio of 135.09. The company has a 50-day moving average of $42.61 and a 200 day moving average of $41.42. GlaxoSmithKline PLC has a 52 week low of $37.24 and a 52 week high of $45.49.

The business also recently announced a dividend, which was paid on Thursday, July 14th. Stockholders of record on Friday, May 13th were paid a dividend of $0.549 per share. The ex-dividend date was Wednesday, May 11th.

A number of other equities research analysts have also recently commented on the stock. Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, June 23rd. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, June 21st. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “hold” rating in a research report on Monday, April 18th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, April 25th. Finally, Cowen and Company cut shares of GlaxoSmithKline PLC from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 26th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and a consensus target price of $46.86.

Several hedge funds recently modified their holdings of the stock. MUFG Americas raised its stake in shares of GlaxoSmithKline PLC by 11.3% in the third quarter. MUFG Americas now owns 73,060 shares of the pharmaceutical company’s stock worth $2,809,000 after buying an additional 7,399 shares in the last quarter. Beacon Financial Group raised its stake in shares of GlaxoSmithKline PLC by 4.1% in the fourth quarter. Beacon Financial Group now owns 146,882 shares of the pharmaceutical company’s stock worth $6,028,000 after buying an additional 5,799 shares in the last quarter. Sei Investments Co. raised its stake in shares of GlaxoSmithKline PLC by 33.8% in the fourth quarter. Sei Investments Co. now owns 55,190 shares of the pharmaceutical company’s stock worth $2,228,000 after buying an additional 13,949 shares in the last quarter. First Trust Advisors LP raised its stake in shares of GlaxoSmithKline PLC by 14.4% in the fourth quarter. First Trust Advisors LP now owns 183,577 shares of the pharmaceutical company’s stock worth $7,407,000 after buying an additional 23,157 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of GlaxoSmithKline PLC by 5.1% in the fourth quarter. Rhumbline Advisers now owns 26,550 shares of the pharmaceutical company’s stock worth $1,071,000 after buying an additional 1,300 shares in the last quarter.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.